Anti-TNF-α and Th1 cytokine-directed therapies for the treatment of asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 1, 2006, Pages 43-50

  Cazzola, Mario ^a   Polosa, Riccardo ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Asthma; Biological therapy; IFN ; IL 12; IL 18; IL 2; TNF

Indexed keywords

5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (3 MORPHOLINOPROPYL)IMIDAZOLE; ADALIMUMAB; ADENOVIRUS VECTOR; ALLERGEN; ANTISENSE OLIGONUCLEOTIDE; BASILIXIMAB; BRONCHODILATING AGENT; CJ 14877; CJ 14897; CORTICOSTEROID; CYTOKINE; DACLIZUMAB; DEXAMETHASONE; DNA VACCINE; ETANERCEPT; GAMMA INTERFERON; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 18; ISIS 104838; ISIS 25302; OVALBUMIN; PKF 241 466; PKF 242 484; PREDNISOLONE; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; INTERFERON;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLERGIC ASTHMA; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; EFFECTOR CELL; EOSINOPHIL; GRANULOCYTE; HEART ARRHYTHMIA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; TARGET ORGAN; TH1 CELL; TH2 CELL; TREATMENT FAILURE; TREATMENT PLANNING; ANIMAL; CELLULAR IMMUNITY; DRUG ANTAGONISM; IMMUNOLOGY;

ANIMALS; ASTHMA; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; INTERFERONS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746713752     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000199798.10047.74     Document Type: Review

References (113)

1. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 175:5-14.
2. Heaton T, Rowe J, Turner S, et al. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet 2005; 365:142-149.
3. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000; 105:399-408.
4. Umetsu DT, McIntire JJ, Akbari O, et al. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002; 3:715-720.
5. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999; 103:175-183.
6. Randolph DA, Carruthers CJ, Szabo SJ, et al. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999; 162:2375-2383.
7. Holtzman MJ, Agapov E, Kim E, et al. Developing the epithelial, viral, and allergic paradigm for asthma. Chest 2003; 123:377S-384S.
8. Hogan SP, Mould A, Kikutani H, et al. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997; 99:1329-1339.
9. Mehlhop PD, van de Rijn M, Goldberg AB, et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci U S A 1997; 94:1344-1349.
10. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2261.
11. Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183:109-117.
12. Foster PS, Hogan SP, Ramsay AJ, et al. IL-5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1995; 183:195-201.
13. Holtzman MJ, Sampath D, Castro M, et al. The one-two of T helper cells: does interferon-γ knockout the Th2 hypothesis for asthma? Am J Respir Cell Mol Biol 1996; 14:316-318.
14. Hakonarson H, Bjornsdottir US, Ostermann E, et al. Allelic frequencies and patterns of single-nucleotide polymorphisms in candidate genes for asthma and atopy in Iceland. Am J Respir Crit Care Med 2001; 164:2036-2044.
15. Hales BJ, Shen H, Thomas WR. Cytokine responses to Der p 1 and Der p 7: house dust mite allergens with different IgE-binding activities. Clin Exp Allergy 2000; 30:934-943.
16. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyperresponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167:1734-1739.
17. Okamura H, Kashiwamura S, Tsutsui H, et al. Regulation of interferon-γ production by IL-12 and IL-18. Curr Opin Immunol 1998; 10:259-264.
18. Tang C, Inman MD, van Rooijen N, et al. Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFNgamma-dependent mechanism. J Immunol 2001; 166:1471-1481.
19. Lack G, Bradley KL, Hamelmann E, et al. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice. J Immunol 1996; 157:1432-1439.
20. Swain SL, Bradley LM, Croft M, et al. Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 1991; 123:115-144.
21. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation, I: IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988; 140:4245-4252.
22. Morita M, Lamkhioued B, Soussi Gounni A, et al. Induction by interferons of human eosinophil apoptosis and regulation by interleukin-3, granulocyte/macrophage-colony stimulating factor and interleukin-5. Eur Cytokine Netw 1996; 7:725-732.
23. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995; 16:128-130.
24. H2 responses after allergen challenge in sensitized interferon-deficient mice. Am J Respir Crit Care Med 2002; 166:451-456.
25. Benjaponpitak S, Oro A, Maguire P, et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-475.
26. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996; 97:1356-1365.
27. Dery RE, Bissonnette EY. IFN-γ potentiates the release of TNF-α and MIP-α by alveolar macrophages during allergic reactions. Am J Respir Cell Mol Biol 1999; 20:407-412.
28. Ten Hacken NHT, Oosterhoff Y, Kauffman HF, et al. Elevated serum interferon-γ in atopic asthma correlates with increased airways responsiveness and circadian peak expiratory flow variation. Eur Respir J 1998; 11:312-316.
29. Krug N, Madden J, Redington AE, et al. T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol 1996; 14:319-326.
30. Warner JA, Miles EA, Jones AC, et al. Is deficiency of interferon γ production by allergen triggered cord blood cells a predictor of atopic eczema? Clin Exp Allergy 1994; 24:423-430.
31. Renzi PM, Turgeon JP, Marcotte JE, et al. Reduced interferon-γ production in infants with bronchiolitis and asthma. Am J Respir Crit Care Med 1999; 159:1417-1422.
32. van Schaik SM, Tristram DA, Nagpal IS, et al. Increased production of IFN-γ and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999; 103:630-636.
33. Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995; 95:133-135.
34. Benjaponpitak S, Oro A, Maguire P, et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-475.
35. Gratzl S, Palca A, Schmitz M, Simon HU. Treatment with IFN-α in corticosteroid-unresponsive asthma. J Allergy Clin Immunol 2000; 105:1035-1036.
36. Gao Z, Kang Y, Xu Y, et al. Inhibition of allergic responsiveness in a murine asthma model via IFN-γ transgene expression. Chin Med J 2002; 115:1470-1474.
37. Reisinger J, Triendl A, Kuchler E, et al. IFN-γ-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J Allergy Clin Immunol 2005; 115:973-981.
38. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193:1007-1008.
39. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73:5-8.
40. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76:263-274.
41. Rand TH, Silberstein DS, Kornfeld H, Weller PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991; 88:825-832.
42. Sedgwick JB, Frick WE, Sandel PM, et al. The appearance of hypodense eosinophils during interleukin-2 treatment. J Allergy Clin Immunol 1990; 85:557-566.
43. Macdonald D, Gordon AA, Kajitani H, et al. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol 1990; 76:168-173.
44. Nakamura Y, Ozaki T, Kamei T, et al. Increased granulocyte/macrophage colony-stimulating factor production by mononuclear cells from peripheral blood of patients with bronchial asthma. Am Rev Respir Dis 1993; 147:87-89.
45. Enokihara H, Furusawa S, Nakakubo H, et al. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 1989; 73:1809-1813.
46. Renzi PM, Du T, Sapienza S, et al. Acute effects of interleukin-2 on lung mechanics and airway responsiveness in rats. Am Rev Respir Dis 1991; 143:380-385.
47. Renzi PM, Sapienza S, Waserman S, et al. Effect of interleukin-2 on the airway response to antigen in the rat. Am Rev Respir Dis 1992; 146:163-169.
48. Conesa A, Tassinari P, Aldrey O, et al. Interleukin-2 induces peroxide production by primed normodense eosinophils of patients with asthma. Allergy Asthma Proc 2003; 24:27-33.
49. Walker C, Bode E, Boer L, et al. Allergic and non-allergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992; 146:109-115.
50. Broide D, Paine MM, Firestein GS. Eosinophils express interleukin S and granulocyte-macrophage colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90:1414-1424.
51. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
52. Bentley AM, Meng Q, Robinson DS, et al. Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993; 8:35-42.
53. Leung DYM, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon γ gene expression in steroid-resistant asthma. J Exp Med 1995; 181:33-40.
54. Sornasse TR, Hong W, Schreck R, et al. Daclizumab in vitro inhibits the secretion of pro-asthmatic and pro-inflammatory cytokines by activated T cells [abstract]. J Allergy Clin Immunol 2005; 115:S73.
55. Busse WW, Baker JW, Charous BL, et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma [abstract]. J Allergy Clin Immunol 2004; 113:S286-S287.
56. Nelson HS, Busse WW, Israel E, et al. Daclizumab improves asthma control in patients with refractory asthma [abstract]. J Allergy Clin Immunol 2005; 115:S134.
57. Tan J, Yang S, Wu W. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients. Transplant Proc 2005; 37:903-905.
58. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-4027.
59. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-276.
60. Lee Y, Fu C, Chiang B. Administration of interleukin-12 exerts a therapeutic instead of a long-term preventive effect on mite Der p I allergen-induced animal model of airway inflammation. Immunology 1999; 97:232-240.
61. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-549.
62. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76:241-251.
63. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 1996; 4:471-481.
64. Kips JC, Brusselle GJ, Joos GF, et al. Interleukin-12 inhibits antigen-induced airway hyper-responsiveness in mice. Am J Respir Crit Care Med 1996; 153:535-539.
65. Schwarze J, Hamelmann E, Cieslewicz G, et al. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol 1998; 102:86-93.
66. Sur S, Bouchard P, Holbert D, Van Scott MR. Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. Exp Lung Res 2000; 26:477-489.
67. van der Pouw Kraan TC, Boeije LC, de Groot ER, et al. Reduced production of IL-12 and IL-12-dependent IFN-γ release in patients with allergic asthma. J Immunol 1997; 158:5560-5565.
68. Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997; 155:845-851.
69. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997; 90:2541-2548.
70. Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149-2153.
71. Kim TS, DeKruyff RH, Rupper R, Maecker HT, et al. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997; 158:4137-4144.
72. Matsuse H, Kong X, Hu J, et al. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity. Int Immunopharmacol 2003; 3:457-468.
73. Leonard P, Sur S. Interleukin-12: potential role in asthma therapy. BioDrugs 2003; 17:1-7.
74. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998; 161:3400-3407.
75. El-Mezayen RE, Matsumoto T. In vitro responsiveness to IL-18 in combination with IL-12 or IL-2 by PBMC from patients with bronchial asthma and atopic dermatitis. Clin Immunol 2004; 111:61-68. This elegant study provided documentation about the role of IL-18 in increasing IFN-γ production through an IL-12-dependent pathway.
76. Suemoto Y, Okamoto I, Usui M, et al. IFN-γ -inducing factor (IGIF) is a co-stimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158:1541-1550.
77. Hofstra CL, Van Ark I, Hofman G, et al. Prevention of Th2-like cell responses by co-administration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol 1998; 161:5054-5060.
78. Ho LP, Davis M, Denison A, et al. Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. Chest 2002; 121:1421-1426.
79. Kumano K, Nakao A, Nakajima H, et al. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airways. Am J Respir Crit Care Med 1999; 160:873-878.
80. Wong CK, Ho CY, Ko FW, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001; 125:177-183.
81. Tanaka H, Miyazaki N, Oashi K, et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 2001; 107:331-336.
82. Tanaka T, Tsutsui H, Yoshimoto T, et al. Interleukin-18 is elevated in sera from patients with atopic dermatitis and from atopic dermatitis model mice. NC/Nga Int Arch Allergy Immunol 2001; 125:236-240.
83. Walter DM, Wong CP, DeKruyff RH, et al. Il-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity. J Immunol 2001; 166:6392-6398.
84. Maecker HT, Hansen G, Walter DM, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001; 166:959-965.
85. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334:1717-1725.
86. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001; 13:389-400.
87. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745-756.
88. Russo C, Polosa R. TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005; 109:135-142. This is one of the first review articles underscoring the importance of TNF-α signaling in the context of asthma and bronchial hyperresponsiveness. The potential role of TNF-α as a therapeutic target in severe chronic asthma is also reviewed here.
89. Lassalle P, Gosset P, Delneste Y, et al. Modulation of adhesion molecule expression on endothelial cells during the late asthmatic reaction: role of macrophage-derived tumour necrosis factor-α. Clin Exp Immunol 1993; 94:105-110.
90. Yamamoto H, Sedgwick JB, Busse WW. Differential regulation of eosinophil adhesion and transmigration by pulmonary microvascular endothelial cells. J Immunol 1998; 161:971-977.
91. Paulsson Y, Austgulen R, Hofsli E, et al. Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts. Exp Cell Res 1989; 180:490-496.
92. Palombella VJ, Mendelsohn J, Vilcek J. Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. J Cell Physiol 1988; 135:23-31.
93. Polosa R, Sapsford RJ, Dokic D, et al. Induction of the epidermal growth factor receptor and its ligands in nasal epithelium by ozone. J Allergy Clin Immunol 2004; 113:120-126.
94. Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA. Elevated release of tumor necrosis factor-α and interferon-γ by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993; 147:291-295.
95. Michel O, Ginanni R, Le Bon B, et al. Inflammatory response to acute inhalation of endotoxin in asthmatic patients. Am Rev Respir Dis 1992; 146:352-357.
96. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor a and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 88:561-571.
97. Amrani Y, Chen H, Panettieri RA Jr. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir Res 2000; 1:49-53.
98. Kips JC, Tavernier J, Pauwels RA. Tumor necrosis factor causes bronchial hyper-responsiveness in rats. Am Rev Respir Dis 1992; 145:332-336.
99. Pennings HJ, Kramer K, Bast A, et al. TNF-α induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. Eur Respir J 1998; 12:45-49.
100. Renzetti LM, Paciorek PM, Tannu SA, et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996; 278:847-853.
101. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152:76-80.
102. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57:774-778.
103. Toussirot E, Wendling D. The use of TNF-α blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5:581-594.
104. Khalil Saadeh C, Brown DM, Chumney-Malacara J, Crow J. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status [abstract]. J Allergy Clin Immunol 2002; 109:s243.
105. Howarth PH, Babu KS, Arshad HS, et al. Tumour Necrosis Factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid- dependent asthma. Thorax 2005 Sep 15 [Epub ahead of print]. This was the first study to show that TNF-α blocking agents can improve symptoms, lung function and bronchial hyperresponsiveness in chronic severe asthma. It also provides evidence that TNF-α production is increased in these patients.
106. Berry MA, Hargadon B, Shelley M, et al. Etanercept in refractory asthma: a randomised controlled trial [abstract]. Am J Respir Crit Care Med 2005; 171:A63.
107. Rouhani FN, Meitin CA, Kaler M, et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99:1175-1182. This work indirectly supports the view that only when asthma becomes more severe and chronic, with the acquisition of an altered inflammatory profile towards a Th1-type response, may anti-TNF-α strategies become useful.
108. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001; 34:50s-59s.
109. van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:465-469.
110. Russo C, D'Angelo F, Polosa R. Study of infliximab treatment in smokers with COPD: What next? Am J Respir Crit Care Med (in press).
111. Trifilieff A, Walker C, Keller T, et al. Pharmacological profile of PKF242-484 andPKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2002; 135:1655-1664.
112. Boehm JC, Smietana JM, Sorenson ME, et al. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J Med Chem 1996; 39:3929-3937.
113. Nyce J. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Curr Opin Allergy Clin Immunol 2002; 2:533-536.